Search
Trastuzumab per al tractament del càncer gàstric o d'unió gastroesofàgica metàstasic HER2+: informe d'avaluació de resultats
(2018)
Trastuzumab is a humanized monoclonal antibody against human epidermal growth factor (HER2) receptor 2, which in 2010 was approved by the European Agency of the
Medication (EMA) for the treatment of gastric cancer or ...
Guanfacina: tractament del trastorn per dèficit d'atenció amb hiperactivitat (TDAH) en nens i adolescents de 6 a 17 anys quan els estimulants no són adequats, no es toleren o han mostrat ser ineficaços
(2017-10)
Attention Deficit Hyperactivity Disorder (ADHD) is a disorder of neurobiological origin that starts at the age of children and affects between 3% and 7% of school-age children. Race with three types of nonspecific symptoms: ...
Tractament farmacològic de la malaltia d’Alzheimer: informe del Registre de Tractament Farmacològic de la Malaltia d’Alzheimer a l’any 2018
(2019)
Alzheimer's disease (MA) is a progressive and irreversible neurodegenerative disorder usually a slow but sustained development over time. MA is the most frequent cause of dementia (69%). Its prevalence is 5.1% and increases ...
Riscos de fàrmacs que empitjoren la funció cognitiva en gent gran: hipnosedants, anticolinèrgics i estatines
(2016-07)
The consumption of hypnosis, anticholinergic drugs and statins is concentrated in the old people. These medications can affect cognitive functions and cause confusion. The risk of confusion and dementia seems to be related ...
Fluoroquinolones i problemes tendinosos
(2015)
The aim is to raise awareness of the proportion of patients treated with fluoroquinolones who subsequently contact a healthcare device for a tendon problem and to establish a methodology that allows this type of analysis ...
Venetoclax en monoteràpia per al tractament de la leucèmia limfocítica crònica
(2019-02-01)
Chronic lymphocytic leukemia (LLC) is the most frequent type of leukemia in adults in the western world, representing 25-50% of all leukemia. The median age at diagnosis is 72 years and only 10% of patients are <55 years. ...